Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use
Advanced pancreatic cancer results in high morbidity and mortality. The standard of care treatment in the advanced setting changed in 2011 with the introduction of FOLFIRINOX (FFX) chemotherapy. However, it was highly toxic with significant risk of complications. We assessed the practice patterns of...
Saved in:
| Main Authors: | Joanna Gotfrit, Horia Marginean, Yoo-Joung Ko, Akmal Ghafoor, Petr Kavan, Haji Chalchal, Shahid Ahmed, Karen Mulder, Patricia Tang, Rachel Goodwin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/128 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FOLFIRINOX for advanced pancreatic adenocarcinoma in Brazil: a single-institution experience
by: José Mauricio Mota, et al.
Published: (2018-01-01) -
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
by: Adam R. Wolfe, et al.
Published: (2020-07-01) -
Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer
by: Manoj Amrutkar, et al.
Published: (2025-02-01) -
Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer
by: Ji Hye Min, et al.
Published: (2025-02-01) -
Prediction of surgical resectability after FOLFIRINOX chemotherapy for borderline resectable and locally advanced pancreatic cancer (PeRFormanCe): a multicenter prospective trial - trial protocol
by: Luís Filipe Abreu de Carvalho, et al.
Published: (2025-05-01)